Baidu
map

感染

订阅

MedSci主页 / 所有栏目 / 感染

SCI TRANSL MED：广谱新药GS-5734可有效抵御冠状病毒

2017-06-30 cailingrui MedSci原创

冠状病毒抗病毒药物
关注

GS-5734对病毒的预防性和早期治疗作用，显著降低了肺部病毒量，极大地改善了临床症状和呼吸机能。这些数据为GS-5734可以有效对抗中东呼吸综合征冠状病毒和人类冠状病毒提供了有力证据，更为抵御将来可能出现的新的冠状病毒起着重要作用。

新兴的病毒感染通常难以控制，因为异质性的病毒会周期性循环进出人类和动物宿主，使得具有针对性的抗病毒治疗和疫苗的研发变得极为复杂。冠状病毒(Coronaviruses, CoVs) 具有迅速在新宿主物种中传播并引起严重疾病的能力。严重急性呼吸系统综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)相继出现，导致严重的流行性呼吸疾病在全球迅速传播。能够抑制冠状病毒传染的广谱疗法将会立即解决医疗需求的缺口，在治疗新发的和地方性的冠状病毒感染中都将有着不可估量的价值。

研究结果显示，尚处于临床研发阶段用于治疗埃博拉病毒的核酸前体药物GS-5734，可以有效抑制体外培养环境中的SARS-CoV和MERS-CoV复制。GS-5734还可以有效对抗蝙蝠冠状病毒，流行性 蝙蝠冠状病毒，主要在人类肺细胞中传播流行的人类冠状病毒等，都展示了其抗冠状病毒的光谱性。

在SARS-CoV发病机制的小鼠模型中，GS-5734对病毒的预防性和早期治疗作用，显著降低了肺部病毒量，极大地改善了临床症状和呼吸机能。这些数据为GS-5734可以有效对抗中东呼吸综合征冠状病毒和人类冠状病毒提供了有力证据，更为抵御将来可能出现的新的冠状病毒起着重要作用。

原始出处：
Timothy P. Sheahan, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine. 28 Jun 2017:Vol. 9, Issue 396, eaal3653
本文系梅斯医学（MedSci）原创编译整理，转载需授权！



版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-12-14 bsmagic9140

    #TRA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-11-11 ms5768352621950538

    #GS-5734#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2018-06-01 ms3025846204744509

    #Transl#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-02 1dd8c52fm63(暂无匿称)

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-02 ms3994565386320060

    #Med#

    0

相关资讯

Nature：科学家发现中和冠状病毒的新线索

图片来源：medicalxpress.com 2003年发生的SARS（严重急性呼吸器官综合征）引发了至少775人死亡，2012年MERS（中东呼吸综合征）又开始在人群中肆虐，其病死率为36%，这些疾病均是由冠状病毒而引发的，该病毒可以发生快速进化，从而从动物群体中传染至人类机体。 近日刊登于国际杂志Nature上的一项研究论文中，来自斯克利普斯研究所、达特茅斯医学院及美国国立卫生研究院等

Nat Commun:中科院微生物所高福研究组等揭示MERS-CoV和SARS-CoV刺突蛋白的结构与功能

2017年4月10日，国际学术权威刊物自然出版集团旗下子刊《Nature Communications》杂志上在线发表了中国科学院微生物研究所高福、施一研究组和生物物理研究所研究员章新政研究组合作的一篇研究论文，研究解析了近原子分辨率的MERS-CoV和SARS-CoV三聚体刺突蛋白(Spike glycoprotein，S)的电镜结构，与之前发表的其它冠状病毒S蛋白相比，他们发现这两种高致病性病

STM：新型冠状病毒中和抗体初研成功能

    中美两个独立的研究团队28日报告说，他们发现了多株可以抑制新型冠状病毒(中东呼吸系统综合征冠状病毒)感染的中和抗体。 这是国际上首次报告发现抗新型冠状病毒的中和抗体。中和抗体是免疫细胞分泌的一类蛋白，能在某些病毒侵入细胞之前与该病毒结合，阻止其黏附、感染细胞，相当于把病毒“中和”掉。 清华大学张林琦教授和王新泉教授带领的团

MERS病例飙升敲响警钟

由于担心MERS传染，利雅得球场工作人员戴口罩进行工作 图片来源：FAYEZ NURELDINE 科学家正努力弄清中东呼吸系统综合征（MERS）冠状病毒感染人数急剧增加的原因。仅在4月，沙特阿拉伯和阿拉伯联合酋长国已经报告超过200个新病例。美国疾病控制和预防中心也于5月2日通报说，该国确诊境内首位感染MERS病毒的患者，并称不排除因患者此前接触他人而造成更大范围传播

PNAS：发现对抗MERS冠状病毒的抗体

一个国际研究小组发现了一种MERS中和抗体，该发现可能会对MERS病毒感染者的治疗有帮助。他们的文章发表在《美国国家科学院学报》上，该研究小组描述了他们进行的研究结果以及为什么他们认为他们所发现的可能会对这种致命的疾病能够预防和治疗。 中东呼吸系统综合症冠状病毒(MERS-CoV)是一种疾病，它会导致严重的呼吸道疾病感染并且死亡率很高。它被认为中东地区的人类从骆驼(骆驼的病毒来自蝙蝠)身上

我国科学家发现冠状病毒编码校正分子机制

中科院上海生科院生化细胞所国家蛋白质科学中心·上海（筹）特聘研究员兼清华大学教授饶子和与该中心研究员张荣光领导团队，在新发MERS/SARS冠状病毒研究中取得重要进展，首次揭示了nsp14-nsp10复合体的结构基础，阐明了冠状病毒编码校正的分子机制，相关研究成果已在线发表于美国《国家科学院院刊》。 冠状病毒是目前基因组最大的一种RNA病毒，能够感染人类，引起多种急性和慢性疾病，其中最引人

Baidu
map
Baidu
map
Baidu
map